Margareth Zuluaga Aricapa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Margareth Zuluaga Aricapa has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Mondragón-Quiguanas
Santiago de Cali District Public Health Secretariat, Santiago de Cali Mayor’s Office, Santiago de Cali 760045, Colombia
1 shared publication - Bruno Gutiérrez
Universidad del Valle
1 shared publication - Carlos Eduardo Pinzón Flórez
Santiago de Cali District Public Health Secretariat, Santiago de Cali Mayor’s Office, Santiago de Cali 760045, Colombia
1 shared publication - German Escobar Morales
Santiago de Cali District Public Health Secretariat, Santiago de Cali Mayor’s Office, Santiago de Cali 760045, Colombia
1 shared publication - Johana Alejandra Moreno-Drada
Escuela de Odontología, Facultad de Salud, Universidad del Valle, Cali, Colombia
1 shared publication - Jorge Iván Montoya Salazar
Santiago de Cali District Public Health Secretariat, Santiago de Cali Mayor’s Office, Santiago de Cali 760045, Colombia
1 shared publication
Latest Publications
- Open Access
Profile of Priority Antimicrobial-Resistant Pathogens and the Behavior of Multidrug-Resistant Tuberculosis in the Santiago de Cali District, Colombia
Background: Antimicrobial resistance is a threat that increases morbidity and mortality. This cross-sectional study aimed to describe the profile of priority antimicrobial-resistant pathogens and to analyze the behavior of multidrug-resistant tuberculosis (MDR-TB) in the Santiago de Cali District, Colombia. Methods: researchers compiled information from data provided by healthcare institutions, the National Public Health Surveillance System, and laboratory-based surveillance using the World Health Organization’s WHONET v.5.6 software. Univariate statistical analysis described trends in pathogen resistance, and multivariate analysis analyzed the behavior of MDR-TB. Results: Among Gram-negative bacteria, high levels of carbapenem resistance were observed in A. baumannii (84% aztreonam resistance) and in K. pneumoniae (63%). P. aeruginosa exhibited elevated multidrug resistance, consistent with extensive antimicrobial selective pressure. MDR-TB exhibited a high burden of resistance, reaching 96%, with projections indicating a potential increase driven by monoresistance and resistance to rifampicin. Patients with drug-resistant tuberculosis who were HIV-positive or experiencing homelessness had a significantly higher likelihood of hospitalization (OR 5.59; 95% CI 3.09–10.11 and OR 2.94; 95% CI 1.48–5.81, respectively) and mortality (OR 3.34; 95% CI 1.72–6.49 and OR 2.59; 95% CI 1.16–5.79, respectively). Conclusions: The expansion of resistance mechanisms suggests sustained selective pressure, underscoring the need for strategies to optimize antibiotics.
Open AccessProfile of Priority Antimicrobial-Resistant Pathogens and the Behavior of Multidrug-Resistant Tuberculosis in the Santiago de Cali District, Colombia
Background: Antimicrobial resistance is a threat that increases morbidity and mortality. This cross-sectional study aimed to describe the profile of priority antimicrobial-resistant pathogens and to analyze the behavior of multidrug-resistant tuberculosis (MDR-TB) in the Santiago de Cali District, Colombia. Methods: researchers compiled information from data provided by healthcare institutions, the National Public Health Surveillance System, and laboratory-based surveillance using the World Health Organization’s WHONET v.5.6 software. Univariate statistical analysis described trends in pathogen resistance, and multivariate analysis analyzed the behavior of MDR-TB. Results: Among Gram-negative bacteria, high levels of carbapenem resistance were observed in A. baumannii (84% aztreonam resistance) and in K. pneumoniae (63%). P. aeruginosa exhibited elevated multidrug resistance, consistent with extensive antimicrobial selective pressure. MDR-TB exhibited a high burden of resistance, reaching 96%, with projections indicating a potential increase driven by monoresistance and resistance to rifampicin. Patients with drug-resistant tuberculosis who were HIV-positive or experiencing homelessness had a significantly higher likelihood of hospitalization (OR 5.59; 95% CI 3.09–10.11 and OR 2.94; 95% CI 1.48–5.81, respectively) and mortality (OR 3.34; 95% CI 1.72–6.49 and OR 2.59; 95% CI 1.16–5.79, respectively). Conclusions: The expansion of resistance mechanisms suggests sustained selective pressure, underscoring the need for strategies to optimize antibiotics.
- Open Access
- 14 May 2024
- Published by American Field Epidemiology Association in American Journal of Field Epidemiology
- Vol. 1 (4) , S8
Brote por Ralstonia insidiosa, en tres sedes de una institución de salud, Cali, Colombia, 2022
Antecedentes: El 18 de mayo de 2022, la secretaría de salud distrital de Cali recibió una alerta de una IPS de nivel IV que notificó aislamiento de Ralstonia insidiosa en hemocultivos de cinco pacientes con bacteriemia, hospitalizados en tres sedes de dicha IPS, en un período de cuatro días. Desde el año 2013, la IPS no reportaba casos con este microorganismo y, dado el aumento inusitado del microorganismo, se confirmó el brote y se procedió a orientar la investigación epidemiológica para la trazabilidad de los medicamentos administrados e identificar fuente
- 14 May 2024
- Published by American Field Epidemiology Association in American Journal of Field Epidemiology
- Vol. 1 (4) , S8
Open AccessBrote por Ralstonia insidiosa, en tres sedes de una institución de salud, Cali, Colombia, 2022
Antecedentes: El 18 de mayo de 2022, la secretaría de salud distrital de Cali recibió una alerta de una IPS de nivel IV que notificó aislamiento de Ralstonia insidiosa en hemocultivos de cinco pacientes con bacteriemia, hospitalizados en tres sedes de dicha IPS, en un período de cuatro días. Desde el año 2013, la IPS no reportaba casos con este microorganismo y, dado el aumento inusitado del microorganismo, se confirmó el brote y se procedió a orientar la investigación epidemiológica para la trazabilidad de los medicamentos administrados e identificar fuente